Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,934.88 +2,223.90 (+3.38%) CMC Crypto 200
1,361.88 +31.28 (+2.33%)
PAVmed Inc. (PAVM)
After hours:
| Previous close | 1.0400 |
| Open | 1.0200 |
| Bid | 0.9879 x 100 |
| Ask | 1.0500 x 100 |
| Day's range | 1.0100 - 1.0600 |
| 52-week range | 0.6000 - 9.0000 |
| Volume | |
| Avg. volume | 66,695 |
| Market cap | 9.573M |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.0000 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.75 |
PR NewswireLucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it performed a record number of commercial EsoGuard® Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent a 31% increase sequentially from the first quarter.
- PR Newswire
Lucid Diagnostics Launches New Corporate Website
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the launch of its newly redesigned corporate website, www.luciddx.com.
- PR Newswire
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive data from its ESOGUARD BE-1 prospective, international, multicenter, single-arm study conducted to clinically validate performance of the EsoGuard® Esophageal DNA test on samples collected with the EsoCheck® Esophageal Cell Collection Device for detection of esophageal precancer (B
